At 7.3% CAGR, the Middle East & Africa Breast Cancer Therapeutics Market Is Projected to be Worth US$ 1,342.86 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Middle East & Africa breast cancer therapeutics market was valued at US$ 762.61 million in 2022 and is expected to reach US$ 1,342.86 million by 2030, registering a CAGR of 7.3% from 2022 to 2030. Increasing use of personalized medicine and rising cancer of breast cancer incidences are among the critical factors attributed to the Middle East & Africa breast cancer therapeutics market expansion.

Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patients cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancers growth by analyzing a patients tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patients tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.

By providing tailored treatments to individual patients, healthcare providers can increase the likelihood of successful outcomes and reduce the risk of unnecessary side effects. In addition to improving patient outcomes, personalized medicine also offers economic benefits. By selecting treatments that are more likely to be effective, healthcare providers can reduce healthcare costs associated with ineffective treatments and avoid unnecessary expenses. As advancements in genomics and molecular diagnostics progress, personalized medicine is likely to become increasingly accessible and integrated into standard treatment protocols in the coming years. Therefore, the increasing use of personalized medicine is anticipated to bring new growth trends in the Middle East & Africa breast cancer therapeutics market.

On the contrary, high cost of diagnosis and treatment hampers the growth Middle East & Africa breast cancer therapeutics market.

Based on drug therapy, the Middle East & Africa breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 61.5% share of the Middle East & Africa breast cancer therapeutics market in 2022, amassing US$ 468.82 million. It is projected to garner US$ 862.50 million by 2030 to expand at 7.9% CAGR during 2022-2030.

In terms of breast cancer type, the Middle East & Africa breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 66.4% share of the Middle East & Africa breast cancer therapeutics market in 2022, amassing US$ 506.30 million. It is projected to garner US$ 926.39 million by 2030 to expand at 7.8% CAGR during 2022-2030.

By distribution channel, the Middle East & Africa breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 74.4% share of Middle East & Africa breast cancer therapeutics market in 2022, amassing US$ 567.54 million. It is projected to garner US$ 1,020.91 million by 2030 to expand at 7.6% CAGR during 2022-2030.

Based on country, the Middle East & Africa breast cancer therapeutics market is categorized into South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Saudi Arabia held 35.9% share of Middle East & Africa breast cancer therapeutics market in 2022, amassing US$ 273.43 million. It is projected to garner US$ 509.69 million by 2030 to expand at 8.1% CAGR during 2022-2030.

Key players operating in the Middle East & Africa breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc, among others.

- In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreements terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally.

- In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com